Zobrazeno 1 - 5
of 5
pro vyhledávání: '"on behalf of the Trial Team"'
Autor:
Jingtao Gao, Mengqiu Gao, Jian Du, Yu Pang, Gary Mao, Nacer Lounis, Nyasha Bakare, Yanxin Jiang, Ying Zhan, Yuhong Liu, Liang Li, on behalf of the Trial Team
Publikováno v:
Trials, Vol 25, Iss 1, Pp 1-17 (2024)
Abstract Introduction The lack of safe, effective, and simple short-course regimens (SCRs) for multidrug-resistant/rifampicin-resistant tuberculosis (MDR/RR-TB) treatment has significantly impeded TB control efforts in China. Methods This phase 4, ra
Externí odkaz:
https://doaj.org/article/544d1e18c34f41158330125060aec91d
Autor:
Mengqiu Gao, Jingtao Gao, Jian Du, Yuhong Liu, Yao Zhang, Liping Ma, Fengling Mi, Liang Li, Shenjie Tang, on behalf of the Trial Team
Publikováno v:
BMC Infectious Diseases, Vol 17, Iss 1, Pp 1-7 (2017)
Abstract Background Shortening the standard 6-month treatment for drug-susceptible pulmonary tuberculosis (DS-PTB) would be a major improvement for TB case management and disease control. Methods We are conducting a randomized, open-label, controlled
Externí odkaz:
https://doaj.org/article/922994e241c2461d9f1252e4b3d1d782
Autor:
M. Loebinger, E. Polverino, F. Blasi, J. Stuart Elborn, J.D. Chalmers, H.A.W.M. Tiddens, H. Goossens, M. Tunney, F.C. Ringhausen, A.T. Hill, R. Pathan, G. Angyalosi, C.S. Haworth, null on behalf of iBEST-1 Trial Team
Publikováno v:
D12. EPIDEMIOLOGY AND THERAPY IN CF AND NON-CF BRONCHIECTASIS.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::37ef74077f0550d5092430b441b16655
https://doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a6201
https://doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a6201
Autor:
Butts C, Ma, Socinski, Pl, Mitchell, Thatcher N, Havel L, Krzakowski M, Nawrocki S, Te, Ciuleanu, Bosquée L, Jm, Trigo, Spira A, Tremblay L, Nyman J, Ramlau R, Wickart-Johansson G, Ellis P, Gladkov O, Jr, Pereira, We, Eberhardt, Helwig C, Andreas Schröder, Fa, Shepherd, Start, On Behalf Of The Trial Team
Publikováno v:
Europe PubMed Central
Summary Background Effective maintenance therapies after chemoradiotherapy for lung cancer are lacking. Our aim was to investigate whether the MUC1 antigen-specific cancer immunotherapy tecemotide improves survival in patients with stage III unresect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::abf12690113394da854f83011ca96d5b
http://hdl.handle.net/2318/142713
http://hdl.handle.net/2318/142713
Autor:
Joyce Yeung, Shaman Jhanji, John Braun, Janet Dunn, Lucy Eggleston, Samuel Frempong, Louise Hiller, Claire Jacques, Monica Jefford, James Mason, Ramani Moonesinghe, Rupert Pearse, Benjamin Shelley, Cecilia Vindrola, on behalf of VITAL trial team
Publikováno v:
Trials, Vol 25, Iss 1, Pp 1-13 (2024)
Abstract Background Improving outcomes after surgery is a major public health research priority for patients, clinicians and the NHS. The greatest burden of perioperative complications, mortality and healthcare costs lies amongst the population of pa
Externí odkaz:
https://doaj.org/article/e36925d16833409fbbfb0c831d4adb24